In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Commentary|Podcasts|March 29, 2024
A Further Examination of Pharmacy Benefit Managers
Author(s)Nicholas Saraceno, Senior Editor
Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.
Advertisement
In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores:
- The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system
- The role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved
- How Xevant helps improve drug cost transparency efforts
- Strategies for affordability Newman would offer the pharma industry that can be implemented immediately
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management service.
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
Big Three Distributors Lean on Specialty for Profit Growth
3
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
4
The System-Level View That Sound Market Access Decisions Are Missing
5